Front-line Advancements to be Presented at Imedex’s 2016 Great Debates and Updates in Gastrointestinal Malignancies Conference

Share Article

Imedex’s Debate-Driven Conference to Highlight Most Relevant Developments in Gastrointestinal Malignancies

“Great Debates and Updates in GI Malignancies gives practicing oncologists an exceptional platform from which to move forward in effectively treating patients with gastrointestinal cancers." -Dr. Axel Grothey

Great Debates and Updates in Gastrointestinal Malignancies, an interactive, debate-driven, 2-day conference highlighting the most relevant developments in gastrointestinal (GI) malignancies will be an unparalleled educational experience for the 250+ healthcare professionals attending on April 1-2, 2016 in New York, New York. As in the past, the meeting will be certified and organized by Imedex, an industry leader in providing CME programs in a live conference setting and online.

“There have been tremendous advancements for the multidisciplinary management of GI cancers in the past decade,” said conference chair Axel Grothey, MD. “Breakthroughs in molecular profiling, cancer immunology, early stage detection, and novel diagnostic techniques have led to accelerated strides in GI cancer research and management.”

As there are currently more than 200 ongoing phase III clinical trials, the field of GI malignancies is continuously evolving. Given the plethora of emerging data and clinical controversies, community oncologists would benefit greatly from expert guidance to resolve several issues in optimizing the management of GI malignancies, including esophageal, gastric, hepatocellular, pancreatic, and colorectal cancers. “Great Debates and Updates in Gastrointestinal Malignancies gives practicing oncologists an exceptional platform from which to move forward in effectively treating patients with gastrointestinal cancers,” said Dr. Grothey.

Covering the broad continuum of gastrointestinal malignancies, from upper GI cancers to lower GI cancers to rare tumors, faculty and audience discussion will be insightful with a focus on how new information fits into current community practice. “The Conference’s interactive format allows faculty and attendees to present, discuss and consider both sides of the treatment paradigm that community oncologists face daily in their practice,” said Chris Bolwell, COO of Imedex. “We are very pleased to once again be partnering with the Conference chairmen and faculty in bringing this educational program to the GI oncology community.”

2016 marks the seventh annual conference, and will be chaired by Axel Grothey, MD (Mayo Clinic) and David H. Ilson, MD, PhD (Memorial Sloan-Kettering Cancer Center). Attendance is expected to push 300 this year, and will likely be the largest annual gathering thus far.

About Imedex
Imedex is an industry leader in providing accredited, independent continuing medical education to health care professionals. We develop high quality scientific programming that translates the latest research into clinically relevant information. The activities have exceptional organization and outstanding educational value, with a proven sustained impact on disease management. Our programs focus on improving patient care around the world. With over 50,000 e-learning experiences annually and more than 100,000 live meeting attendees, since 2001, Imedex truly educates the global healthcare community. At Imedex, education is the best medicine®. For more information on Imedex visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Carlton Sanderson
+1 4047841276
Email >
Follow >
Imedex, LLC
since: 06/2011
Like >

Visit website